Hangzhou Tigermed Consulting (300347) Fundamentals 2026 — P/E 55.4x, Revenue Analysis | SniperIQ
Hangzhou Tigermed Consulting (300347) is a CN-listed Healthcare company in Biotechnology with a market capitalization of ¥36.4B, trading at ¥49.29 on the SHZ. This SniperIQ fundamentals page covers Hangzhou Tigermed Consulting's valuation (P/E 55.4x, P/B 1.9x), profitability (net margin 10.9%), revenue (¥6.8B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Hangzhou Tigermed Consulting's market cap?
Hangzhou Tigermed Consulting (300347) has a market capitalization of approximately ¥36.4B, trading at ¥49.29 on the SHZ. Market cap moves with the live share price.
What is Hangzhou Tigermed Consulting's P/E ratio?
Hangzhou Tigermed Consulting's trailing twelve-month P/E ratio is 55.4x, with a price-to-book (P/B) of 1.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Hangzhou Tigermed Consulting?
Hangzhou Tigermed Consulting runs a net profit margin of 10.9%, a gross margin of 26.6%, and an operating margin of 18.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Hangzhou Tigermed Consulting generate?
Hangzhou Tigermed Consulting reported revenue of ¥6.8B for fiscal year 2025, with net income of ¥888M and earnings per share (EPS) of 1.04. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Hangzhou Tigermed Consulting pay a dividend?
Hangzhou Tigermed Consulting offers a trailing dividend yield of about 0.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Hangzhou Tigermed Consulting financially healthy?
Hangzhou Tigermed Consulting carries a debt-to-equity ratio of 0.08x and a current ratio of 2.30x, with a market beta of 0.41. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Hangzhou Tigermed Consulting a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Hangzhou Tigermed Consulting (300347) the key facts are: market cap ¥36.4B, P/E 55.4x, revenue ¥6.8B, 52-week range 35.57-71.9. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Hangzhou Tigermed Consulting's full fundamentals live
Get Hangzhou Tigermed Consulting's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.